Biogen delays 'complex and unpredecented' Alzheimer’s drug application
April 22, 2020 at 10:20 AM EDT
Biogen previously said it expected to ask the FDA to approve its Alzheimer's drug aducanumab in “early 2020”.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|